Medical artificial intelligence (AI) company Lunit will present the results of a joint study with AstraZeneca at the "2025 American Cancer Research Society (AACR)" to be held in Chicago from the 25th to the 30th of next month. The two companies have been conducting research to predict epithelial cell growth factor receptor (EGFR) mutations in non-small cell lung cancer using AI.

The two companies developed a mutation prediction solution with improved performance compared to existing AI models by applying the AI solution "Lunitscope Genotype Predictor" to more than 12,000 non-small cell lung cancer patients collected by medical institutions around the world. As a result of the study, the accuracy of mutation detection of the Lunit AI solution was 0.880, an AI performance evaluation index. The figure is a significant improvement over the existing AI model's 0.723. "We will speed up the commercialization of EGFR mutation search AI solutions and expand them to predict mutations in other carcinomas," said Seo Beom-seok, CEO of Runit.

[Reporter Kim Jihee]